Ads
related to: progesterone negative breast cancer prognosis- Patient FAQ Answers
View Frequently Asked Questions.
Get Answers To Common Questions.
- Early Breast Cancer
Find Condition Information.
Understand eBC.
- Treatment Information
Read About This Treatment Option.
Learn How This Option May Help.
- Patient Support Program
Access Personalized Support.
View Financial Support Options.
- Patient Resources
Access Helpful Patient Materials.
Download Resources Today.
- Clinical Data
See The Data For This Option.
eBC Clinical Trial Information.
- Patient FAQ Answers
Search results
Results From The WOW.Com Content Network
Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification (i.e. the tumor is negative on all three tests giving the name triple-negative). [1]
This is an accepted version of this page This is the latest accepted revision, reviewed on 29 January 2025. Cancer that originates in mammary glands Medical condition Breast cancer An illustration of breast cancer Specialty Surgical Oncology Symptoms A lump in a breast, a change in breast shape, dimpling of the skin, fluid from the nipple, a newly inverted nipple, a red scaly patch of skin on ...
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
One of these — triple-negative breast cancer (TNBC) — is an aggressive type of breast cancer that tends to grow and spread rapidly, and has a worse prognosis than other breast cancers.
HER/neu-negative PACB is one of the triple-negative breast cancers (TNBCs). TNBCs are a group of estrogen receptor-, androgen receptor-, and HER2/neu-negative tumors that account for 10%-15% of all breast cancers and are particularly aggressive cancers that generally have a poorer prognosis than other breast cancer subtypes. [18]
Staging of breast cancer is one aspect of breast cancer classification that assists in making appropriate treatment choices, when considered along with other classification aspects such as estrogen receptor and progesterone receptor levels in the cancer tissue, the human epidermal growth factor receptor 2 status, menopausal status, and the ...
Ads
related to: progesterone negative breast cancer prognosis